obesity drugs

Novo Nordisk lifts 2026 outlook as Wegovy pill sales beat

Novo Nordisk raised its full-year forecast on Wednesday, November 4, 2026, after a third quarter that came in ahead of expectations. Sales of the Wegovy pill in the US and the older Ozempic injection both beat forecasts. The company now…

Novo Nordisk CEO says company is open to larger M&A deals

Novo Nordisk CEO Mike Doustdar told CNBC on Tuesday that the company is actively considering mergers and acquisitions to fill gaps in its drug portfolio, a day after the Danish drugmaker's Capital Markets Day in London left investors underwhelmed.

Novo Nordisk shares slide after growth plan fails to impress investors

Novo Nordisk shares fell as much as 7% in Copenhagen on Monday after the Danish drugmaker's Capital Markets Day in London failed to convince investors it has a credible near-term plan to sustain growth beyond its blockbuster Wegovy and Ozempic…

Novo Nordisk CEO pledges bolt-on deals after pipeline setbacks sink shares

Novo Nordisk CEO Mike Doustdar on Wednesday pledged to accelerate research and pursue bolt-on acquisitions to rebuild the Danish drugmaker's pipeline, as investors expressed frustration over a string of clinical trial setbacks that have overshadowed an upgraded 2026 outlook.

Novo Nordisk demands price cuts from suppliers amid margin squeeze

Novo Nordisk has written to its suppliers requesting price reductions as the Danish pharmaceutical giant grapples with mounting cost pressures in a rapidly changing weight-loss drug market, according to a report by MedWatch on Wednesday. The correspondence gave suppliers only…